Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.
| Website: | www.karyopharm.com |
| Main Phone: | +1 617 658-0600 |
| Address: | 85 Wells Avenue |
| Address 2: | 2nd Floor |
| State: | MA |
| City / Town: | Newton |
| Country: | USA |
| Postal Code: | 02459 |
| Exchange: | NGS |
| CEO: | Michael G. Kauffman |
| Employees: | 154 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 18.32 | Change $ -0.66 | Change % -3.48 | Tick N/A |
| Bid 18.00 | Bid Size 1,000.00 | Ask 19.98 | Ask Size 500.00 |
| Open 19.01 | High 19.19 | Low 18.13 | Prev Close 18.98 |
| Last Trade | Volume 1.8 mi | 52 Wk Hi 21.71 | 52 Wk Low 9.00 |
| Market Cap 1.1 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 60,563,449.00 | EPS (TTM) -2.84 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 30 | 88 |
| Number of Buys | 16 | 41 |
| Number of Sells | 14 | 47 |
| Net Activity | -2000 | -2763 |
| Last 10 Buys | Shares |
|---|---|
| Ran Frenkel | 1,000 |
| Ran Frenkel | 1,000 |
| Justin A. Renz | 1,000 |
| Barry E. Greene | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Deepika R. Pakianathan | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Michael G. Kauffman | 1,000 |
| Sharon Shacham | 1,000 |
| Sharon Shacham | 1,000 |
| Michael G. Kauffman | 1,000 |
| Christopher Brett Primiano | 1,000 |
| Mansoor Raza Mirza | 1,000 |
| Michael G. Kauffman | 1,000 |
| Sharon Shacham | 1,000 |
| Sharon Shacham | 1,000 |
| Michael G. Kauffman | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 30 | 30 | 30 | 30 |
| Low Target Price Estimate | 14 | 14 | 14 | 14 |
| Mean Target Price Estimate | 22 | 22 | 22.1 | 22 |
| Standard Deviation | 5.16 | 5.16 | 5.11 | 5.16 |
| Date of Most Recent Estimate | 06/02/18 | 05/24/18 | 05/22/18 | 06/02/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| CT ORDER | 1 | 2018-06-14 | |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 8-K | Report of unscheduled material events or corporate changes. | 32 | 2018-06-07 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-05-24 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-10 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 194 | 2018-05-10 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 |
| Moderate Sell | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.6 | 1.4 | 1.4 | 1.4 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
